PDIL2-2 Antibody
Description
Mechanisms of Action in Immune Regulation
PD-L2 antibodies modulate immune responses through:
-
PD-1 Pathway Inhibition: Blocking PD-L2/PD-1 interaction reverses T-cell exhaustion, enhancing anti-tumor immunity .
-
B-Cell Regulation: PD-L2 suppresses B-1a cell differentiation into antibody-secreting cells (ASCs), reducing natural IgM production against phosphorylcholine (PC) and phosphatidylcholine (PtC) .
-
RGMb Signaling: Antibodies may disrupt PD-L2/RGMb interactions, altering BMP-mediated immune tolerance in tissues like the lung .
Cancer Immunotherapy
-
Ovarian Cancer: PD-L2 is overexpressed in ovarian tumors and correlates with poor response to PD-1 inhibitors. Engineered soluble PD-1 (sPD-1) mutants neutralizing PD-L2/PD-L1 improved T-cell activation and tumor suppression in preclinical models .
-
Comparative Efficacy: High-affinity PD-L2 antibodies outperform PD-L1-targeted therapies in cancers co-expressing both ligands .
Autoimmunity and Infection
-
B-1 Cell Modulation: PD-L2 antibodies restore IL-5-dependent ASC differentiation, influencing autoimmune disease progression .
-
Pathogen Defense: PD-L2 blockade enhances IgM-mediated clearance of Haemophilus influenzae expressing PC .
Challenges and Future Directions
-
Specificity: Distinguishing PD-L2 from PD-L1 in co-expressing tumors remains challenging .
-
Combination Therapies: Pairing PD-L2 antibodies with PD-1/PD-L1 inhibitors may overcome resistance in ovarian and gastric cancers .
-
Novel Targets: Research into RGMb-PD-L2 axis could unlock therapies for autoimmune and chronic inflammatory diseases .
Product Specs
Target Background
Q&A
Here’s a structured FAQ collection for researchers studying PD-L2 antibodies in academic contexts, synthesized from peer-reviewed studies and technical documentation:
Advanced Research Questions
What structural techniques resolve PD-L2 antibody epitope diversity?
-
High-resolution methods:
-
X-ray crystallography: Resolve Fab-RBD complexes at ≤2.5 Å resolution to map residues (e.g., ACE2-overlap regions) .
-
Cryo-EM: Visualize antibody binding to trimeric PD-L2 in native conformations .
-
BLI competition assays: Classify antibodies into epitope clusters (e.g., ACE2-blocking vs. non-blocking) .
-
How do I design a multiplex assay integrating PD-L2 detection with immune profiling?
-
Workflow:
How are contradictions in PD-L2 clinical correlations resolved?
-
Analytical framework:
Table 1. PD-L2 Expression in Human Tumors (n=400+)
| Cancer Type | PD-L2+ Stroma (%) | PD-L2+ Tumor Cells (%) | Endothelial Expression |
|---|---|---|---|
| HNSCC | 62 | 38 | Yes |
| NSCLC | 55 | 28 | Rare |
| Melanoma | 41 | 12 | No |
Table 2. Epitope Characteristics of Neutralizing PD-L2 Antibodies
| Antibody Cluster | ACE2 Overlap Residues | Neutralization IC50 (µg/mL) | Structural Class |
|---|---|---|---|
| Cluster 1 | 14/22 | 0.03–0.12 | Competitive |
| Cluster 3 | 1/22 | 0.87 | Non-competitive |
